Syncromune™
Marlene Barton has extensive experience in regulatory affairs and compliance. Marlene is currently serving as the Chief Regulatory & Compliance Officer at Syncromune™ since December 2021. Prior to this, they held the role of President at Wright Regulatory Consulting, LLC from September 2020. Marlene also served as the President at WRC LLC since January 2010.
In their previous roles, Marlene was the EVP, Chief Regulatory and Compliance Officer at ImmunSYS, Inc. from October 2018 to September 2020. Marlene was responsible for the regulatory and compliance aspects of the clinical stage immunotherapeutic development company, with a focus on late-stage metastatic prostate cancer.
Marlene also had a long tenure at Cordis Corporation/Cordis Endovascular Systems (CES) from April 1996 to January 2010. During their time there, they held various positions including Vice President Regulatory Affairs, Director International Regulatory Affairs, Director Regulatory Affairs, and Sr. Manager Regulatory Affairs & Clinical Research, among others. Marlene was responsible for obtaining regulatory approvals worldwide for cardiovascular class II & III medical devices and combination products.
Overall, Marlene Barton has extensive experience in regulatory affairs and compliance, with a focus on the healthcare and medical device industries.
Marlene Barton attended Binghamton University from 1979 to 1983, where they pursued a Bachelor of Science degree in Geology. Additionally, they obtained a Bachelor's degree in Geology/Earth Science, General from the same institution at an unspecified time.
This person is not in any teams
This person is not in any offices
Syncromune™
1 followers
Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers. We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringinglife-changing treatments to patients with unmet medical needs by fighting cancer in a new way. The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor antigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to optimize T cells and the immune system to treat metastatic solid tumors where other therapies have failed.